Erratum to: Dysregulation of matricellular proteins is an early signature of pathology in laminin-deficient muscular dystrophy [Skeletal Muscle, 4, (2014), 14. DOI:10.1186/2044-5040-4-14];Dysregulation of matricellular proteins is an early signature of pathology in laminin-deficient muscular dystrophy

Skeletal Muscle

Volumn 4, Issue 1, 2014, Pages

  Mehuron, Thomas ^a   Kumar, Ajay ^a   Duarte, Lina ^a   Yamauchi, Jenny ^a   Accorsi, Anthony ^a   Girgenrath, Mahasweta ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

Apoptosis; CMD; ECM; Fibrosis; Inflammation; Matricellular; MDC1A

Indexed keywords

MUS;

EID: 84903413911     PISSN: None     EISSN: 20445040     Source Type: Journal    
DOI: 10.1186/2044-5040-4-17     Document Type: Erratum

References (65)

1. Collins J, Bönnemann CG. Congenital muscular dystrophies: toward molecular therapeutic interventions. Curr Neurol Neurosci Rep 2010, 10:83-91.
2. Bönnemann CG, Rutkowski A, Mercuri E, Muntoni F, . for the CMD Outcomes Consortium 173rd ENMC International Workshop: congenital muscular dystrophy outcome measures 5-7 March 2010, Naarden, The Netherlands. Neuromuscul Disord 2011, 21:513-522. for the CMD Outcomes Consortium.
3. Colognato H, Yurchenco PD. Form and function: the laminin family of heterotrimers. Dev Dyn 2000, 218:213-234.
4. Bentzinger CF, Barzaghi P, Lin S, Ruegg MA. Overexpression of mini-agrin in skeletal muscle increases muscle integrity and regenerative capacity in laminin-α2-deficient mice. FASEB J 2005, 19:934-942.
5. Rooney JE, Gurpur PB, Burkin DJ. Laminin-111 protein therapy prevents muscle disease in the mdx mouse model for Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 2009, 106:7991-7996. A published erratum appears in Proc Natl Acad Sci U S A 2009, 106:15514.
6. Gawlik KI, Durbeej M. Transgenic overexpression of laminin α1 chain in laminin α2 chain-deficient mice rescues the disease throughout the lifespan. Muscle Nerve 2010, 42:30-37.
7. Kumar A, Yamauchi J, Girgenrath T, Girgenrath M. Muscle-specific expression of insulin-like growth factor 1 improves outcome in Lama2Dy-w mice, a model for congenital muscular dystrophy type 1A. Hum Mol Genet 2011, 20:2333-2343.
8. Langenbach KJ, Rando TA. Inhibition of dystroglycan binding to laminin disrupts the PI3K/AKT pathway and survival signaling in muscle cells. Muscle Nerve 2002, 26:644-653.
9. Philpot J, Cowan F, Pennock J, Sewry C, Dubowitz V, Bydder G, Muntoni F. Merosin-deficient congenital muscular dystrophy: the spectrum of brain involvement on magnetic resonance imaging. Neuromuscul Disord 1999, 9:81-85.
10. Muntoni F, Voit T. The congenital muscular dystrophies in 2004: a century of exciting progress. Neuromuscular Disord 2004, 14:635-649.
11. Jones KJ, Morgan G, Johnston H, Tobias V, Ouvrier RA, Wilkinson I, North KN. The expanding phenotype of laminin α2 chain (merosin) abnormalities: case series and review. J Med Genet 2001, 38:649-657.
12. Philpot J, Bagnall A, King C, Dubowitz V, Muntoni F. Feeding problems in merosin deficient congenital muscular dystrophy. Arch Dis Child 1999, 80:542-547.
13. Ringelmann B, Röder C, Hallmann R, Maley M, Davies M, Grounds M, Sorokin L. Expression of laminin α1, α2, α4, and α5 chains, fibronectin, and tenascin-C in skeletal muscle of dystrophic 129ReJ dy/dy mice. Exp Cell Res 1999, 246:165-182.
14. Mukasa T, Momoi T, Momoi MY. Activation of caspase-3 apoptotic pathways in skeletal muscle fibers in laminin α2-deficient mice. Biochem Biophys Res Commun 1999, 260:139-142.
15. Miyagoe Y, Hanaoka K, Nonaka I, Hayasaka M, Nabeshima Y, Arahata K, Takeda S. Laminin α2 chain-null mutant mice by targeted disruption of the Lama2 gene: a new model of merosin (laminin 2)-deficient congenital muscular dystrophy. FEBS Lett 1997, 415:33-39.
16. Kuang W, Xu H, Vilquin JT, Engvall E. Activation of the lama2 gene in muscle regeneration: abortive regeneration in laminin α2-deficiency. Lab Invest 1999, 79:1601-1613.
17. Wardrop KE, Dominov JA. Proinflammatory signals and the loss of lymphatic vessel hyaluronan receptor-1 (LYVE-1) in the early pathogenesis of laminin α2-deficient skeletal muscle. J Histochem Cytochem 2011, 59:167-179.
18. Hayashi YK, Tezak Z, Momoi T, Nonaka I, Garcia CA, Hoffman EP, Arahata K. Massive muscle cell degeneration in the early stage of merosin-deficient congenital muscular dystrophy. Neuromuscul Disord 2001, 11:350-359.
19. Taniguchi M, Kurahashi H, Noguchi S, Sese J, Okinaga T, Tsukahara T, Guicheney P, Ozono K, Nishino I, Morishita S, Toda T. Expression profiling of muscles from Fukuyama-type congenital muscular dystrophy and laminin-α2 deficient congenital muscular dystrophy; is congenital muscular dystrophy a primary fibrotic disease?. Biochem Biophys Res Commun 2006, 342:489-502.
20. Noguchi S, Tsukahara T, Fujita M, Kurokawa R, Tachikawa M, Toda T, Tsujimoto A, Arahata K, Nishino I. cDNA microarray analysis of individual Duchenne muscular dystrophy patients. Hum Mol Genet 2003, 12:595-600.
21. Connolly AM, Keeling RM, Mehta S, Pestronk A, Sanes JR. Three mouse models of muscular dystrophy: the natural history of strength and fatigue in dystrophin-, dystrophin/utrophin-, and laminin α2-deficient mice. Neuromuscul Disord 2001, 11:703-712.
22. Whittaker P, Kloner RA, Boughner DR, Pickering JG. Quantitative assessment of myocardial collagen with picrosirius red staining and circularly polarized light. Basic Res Cardiol 1994, 89:397-410.
23. Kamiya Y, Miyazono K, Miyazawa K. Smad7 inhibits transforming growth factor-β family type I receptors through two distinct modes of interaction. J Biol Chem 2010, 285:30804-30813.
24. Zhang S, Fei T, Zhang L, Zhang R, Chen F, Ning Y, Han Y, Feng XH, Meng A, Chen YG. Smad7 antagonizes transforming growth factor β signaling in the nucleus by interfering with functional Smad-DNA complex formation. Mol Cell Biol 2007, 27:4488-4499.
25. Theuer J, Dechend R, Muller DN, Park JK, Fiebeler A, Barta P, Ganten D, Haller H, Dietz R, Luft FC. Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats. BMC Cardiovasc Disord 2002, 2:3.
26. Kim JM, Heo HS, Choi YJ, Ye BH, Mi Ha Y, Seo AY, Yu BP, Leeuwenburgh C, Chung HY, Carter CS. Inhibition of NF-κB-induced inflammatory responses by angiotensin II antagonists in aged rat kidney. Exp Gerontol 2011, 46:542-548.
27. Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, Gamradt M, ap Rhys CM, Holm TM, Loeys BL, Ramirez F, Judge DP, Ward CW, Dietz HC. Angiotensin II type 1 receptor blockade attenuates TGF-β-induced failure of muscle regeneration in multiple myopathic states. Nat Med 2007, 13:204-210. A published erratum appears in Nat Med 2007, 13:511.
28. Allamand V, Guicheney P. Merosin-deficient congenital muscular dystrophy, autosomal recessive (MDC1A, MIM#156225, LAMA2 gene coding for α2 chain of laminin). Eur J Hum Genet 2002, 10:91-94.
29. Voit T, Staub V, Herrmann R. Congenital muscular dystrophies: disorders of the basement membrane and extracellular matrix?. Brain Pathol 2000, 10:498.
30. Reggiani C, Brocks L, Wirtz P, Loermans H, te Kronnie G. Myosin isoforms in hindlimb muscles of normal and dystrophic (ReJ129 dy/dy) mice. Muscle Nerve 1992, 15:199-208.
31. Sandri M, Carraro U. Apoptosis of skeletal muscles during development and disease. Int J Biochem Cell Biol 1999, 31:1373-1390.
32. Vachon PH, Loechel F, Xu H, Wewer UM, Engvall E. Merosin and laminin in myogenesis; specific requirement for merosin in myotube stability and survival. J Cell Biol 1996, 134:1483-1497.
33. Kuang W, Xu H, Vachon PH, Engvall E. Disruption of the lama2 gene in embryonic stem cells: laminin α2 is necessary for sustenance of mature muscle cells. Exp Cell Res 1998, 241:117-125.
34. Girgenrath M, Dominov JA, Kostek CA, Miller JB. Inhibition of apoptosis improves outcome in a model of congenital muscular dystrophy. J Clin Invest 2004, 114:1635-1639.
35. Yamauchi J, Kumar A, Duarte L, Mehuron T, Girgenrath M. Triggering regeneration and tackling apoptosis: a combinatorial approach to treating congenital muscular dystrophy type 1A. Hum Mol Genet 2013, 22:4306-4317.
36. Rutkowski A, Bönnemann C, Brown S, Thorsteinsdóttir S, Dominov J, Ruegg MA, Matter ML, Guttridge D, Crosbie-Watson RH, Kardon G, Nagaraju K, Girgenrath M, Burkin DJ. Report on the Myomatrix Conference April 22-24, 2012, University of Nevada, Reno, Nevada, USA. Neuromuscul Disord 2013, 23:188-191.
37. Frangogiannis NG. Matricellular proteins in cardiac adaptation and disease. Physiol Rev 2012, 92:635-688.
38. Okamoto H, Imanaka-Yoshida K. Matricellular proteins: new molecular targets to prevent heart failure. Cardiovasc Ther 2012, 30:e198-e209.
39. Hartman J, Frishman WH. Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol Rev 2014, 22:147-151.
40. Buckland J. Understanding the link between chronic inflammation and muscle degeneration in myositis. Nat Rev Rheumatol 2014, 10:65.
41. Kumar A, Takada Y, Boriek AM, Aggarwal BB. Nuclear factor-κB: its role in health and disease. J Mol Med (Berl) 2004, 82:434-448.
42. Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin AS. NF-κB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000, 289:2363-2366.
43. Mourkioti F, Rosenthal N. NF-κB signaling in skeletal muscle: prospects for intervention in muscle diseases. J Mol Med (Berl) 2008, 86:747-759.
44. Bakkar N, Guttridge DC. NF-κB signaling: a tale of two pathways in skeletal myogenesis. Physiol Rev 2010, 90:495-511.
45. Thaloor D, Miller KJ, Gephart J, Mitchell PO, Pavlath GK. Systemic administration of the NF-κB inhibitor curcumin stimulates muscle regeneration after traumatic injury. Am J Physiol 1999, 277:C320-C329.
46. O'Regan A, Berman JS. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol 2000, 81:373-390.
47. Zanotti S, Gibertini S, Di Blasi C, Cappelletti C, Bernasconi P, Mantegazza R, Morandi L, Mora M. Osteopontin is highly expressed in severely dystrophic muscle and seems to play a role in muscle regeneration and fibrosis. Histopathology 2011, 59:1215-1228.
48. Uaesoontrachoon K, Wasgewatte Wijesinghe DK, Mackie EJ, Pagel CN. Osteopontin deficiency delays inflammatory infiltration and the onset of muscle regeneration in a mouse model of muscle injury. Dis Model Mech 2013, 6:197-205.
49. Vetrone SA, Montecino-Rodriguez E, Kudryashova E, Kramerova I, Hoffman EP, Liu SD, Miceli MC, Spencer MJ. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-β. J Clin Invest 2009, 119:1583-1594.
50. Uaesoontrachoon K, Yoo HJ, Tudor EM, Pike RN, Mackie EJ, Pagel CN. Osteopontin and skeletal muscle myoblasts: association with muscle regeneration and regulation of myoblast function in vitro. Int J Biochem Cell Biol 2008, 40:2303-2314.
51. Burks TN, Cohn RD. Role of TGF-β signaling in inherited and acquired myopathies. Skelet Muscle 2011, 1:19.
52. Mann CJ, Perdiguero E, Kharraz Y, Aguilar S, Pessina P, Serrano AL, Muñoz-Cánoves P. Aberrant repair and fibrosis development in skeletal muscle. Skelet Muscle 2011, 1:21.
53. Horiuchi K, Amizuka N, Takeshita S, Takamatsu H, Katsuura M, Ozawa H, Toyama Y, Bonewald LF, Kudo A. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor β. J Bone Miner Res 1999, 14:1239-1249.
54. Lorts A, Schwanekamp JA, Baudino TA, McNally EM, Molkentin JD. Deletion of periostin reduces muscular dystrophy and fibrosis in mice by modulating the transforming growth factor-β pathway. Proc Natl Acad Sci U S A 2012, 109:10978-10983.
55. Kudo A. Periostin in fibrillogenesis for tissue regeneration: periostin actions inside and outside the cell. Cell Mol Life Sci 2011, 68:3201-3207.
56. Hamilton DW. Functional role of periostin in development and wound repair: implications for connective tissue disease. J Cell Commun Signal 2008, 2:9-17.
57. Rennard SI, Hunninghake GW, Bitterman PB, Crystal RG. Production of fibronectin by the human alveolar macrophage: mechanism for the recruitment of fibroblasts to sites of tissue injury in interstitial lung diseases. Proc Natl Acad Sci U S A 1981, 78:7147-7151.
58. Moriguchi H, Ozaki T, Yasuoka S, Ogura T. [Production of fibronectin and PGE2 by cultured human alveolar macrophages] [in Japanese]. Nihon Kyobu Shikkan Gakkai Zasshi 1989, 27:1322-1329.
59. Ross J, Benn A, Jonuschies J, Boldrin L, Muntoni F, Hewitt JE, Brown SC, Morgan JE. Defects in glycosylation impair satellite stem cell function and niche composition in the muscles of the dystrophic Largemyd mouse. Stem Cells 2012, 30:2330-2341.
60. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999, 274:21491-21494.
61. Yeghiazaryan M, Żybura-Broda K, Cabaj A, Włodarczyk J, Sławińska U, Rylski M, Wilczyński GM. Fine-structural distribution of MMP-2 and MMP-9 activities in the rat skeletal muscle upon training: a study by high-resolution in situ zymography. Histochem Cell Biol 2012, 138:75-87.
62. Iwashita M, Nakatsu Y, Sakoda H, Fujishiro M, Kushiyama A, Fukushima T, Kumamoto S, Shinjo T, Kamata H, Nishimura F, Asano T. Valsartan restores inflammatory response by macrophages in adipose and hepatic tissues of LPS-infused mice. Adipocyte 2013, 2:28-32.
63. Dorenkamp M, Riad A, Stiehl S, Spillmann F, Westermann D, Du J, Pauschinger M, Noutsias M, Adams V, Schultheiss HP, Tschöpe C. Protection against oxidative stress in diabetic rats: role of angiotensin AT1 receptor and β1-adrenoceptor antagonism. Eur J Pharmacol 2005, 520:179-187.
64. Elbaz M, Yanay N, Aga-Mizrachi S, Brunschwig Z, Kassis I, Ettinger K, Barak V, Nevo Y. Losartan, a therapeutic candidate in congenital muscular dystrophy: studies in the dy2J/dy2J mouse. Ann Neurol 2012, 71:699-708.
65. Meinen S, Lin S, Ruegg MA. Angiotensin II type 1 receptor antagonists alleviate muscle pathology in the mouse model for laminin-α2-deficient congenital muscular dystrophy (MDC1A). Skelet Muscle 2012, 2:18.